What is ADO trastuzumab emtansine used for?
What is ADO trastuzumab emtansine used for?
A drug used to treat certain patients with HER2-positive breast cancer that has already been treated with trastuzumab and a type of anticancer drug called a taxane. It is also being studied in the treatment of other types of cancer.
Is trastuzumab emtansine chemotherapy?
Trastuzumab emtansine (T-DM1) is a novel antibody–drug conjugate, comprised of a potent cytotoxic drug connected via a stable linker to the anti-HER2 antibody, trastuzumab, thereby primarily targeting chemotherapy delivery to cells overexpressing the HER2 receptor.
How does trastuzumab emtansine work in the body?
Trastuzumab attaches to the HER2 proteins (also called receptors) and can stop them growing. It also helps the body’s immune system to destroy cancer cells. When the trastuzumab attaches to the proteins, it delivers emtansine directly into the breast cancer cells.
What is the difference between Kadcyla and Enhertu?
Kadcyla is also approved as an adjuvant therapy for early breast cancer patients with residual disease. Enhertu has a drug antibody ratio (DAR) of eight, compared to Kadcyla’s mean DAR of 3.5, making Enhertu more cytotoxic.
Is Ado-trastuzumab emtansine chemo?
Kadcyla (ado-trastuzumab emtansine) is a new class of chemotherapy drug called an antibody-drug conjugate used to treat breast cancer.
What are the side effects of Enhertu?
The most common side effects of ENHERTU, when used in people with breast cancer, include:
- Nausea.
- Low white blood cell counts.
- Low red blood cell counts.
- Feeling tired.
- Vomiting.
- Hair loss.
- Increased liver function tests.
What are the side effects of Kadcyla?
The most common side effects of Kadcyla are:
- tiredness/fatigue.
- nausea.
- bone and joint pain.
- muscle pain.
- low blood platelet count.
- headache.
- constipation.
- nerve damage.
What is the difference between Kanjinti and Herceptin?
Additional information: Kanjinti is a biosimilar of Herceptin. Herceptin is a monoclonal antibody, “biologic” drug. This means that it is made from living organisms, in this case a protein from a mouse cell.
What is the difference between trastuzumab and emtansine?
Trastuzumab is a type of targeted cancer drug (biological therapy) called monoclonal antibody. Emtansine is a cancer drug that becomes active once Kadcyla enters the cancer cell. Some breast cancers have too much of a protein called human epidermal growth factor receptor 2 (HER2) on the surface of their cells.
When did trastuzumab emtansine trial protocol change?
Randomisation was stratified by world region, number of previous regimens for advanced breast cancer, and presence of visceral disease. On Sept 12, 2012, the study protocol was amended to allow patients with disease progression to crossover from treatment of physician’s choice to trastuzumab emtansine.
How often do you take trastuzumab emtansine for cancer?
The tube stays in place throughout the course of treatment. You have trastuzumab emtansine once every 3 weeks, this is one cycle of treatment. You have the first treatment over 90 minutes.
How does trastuzumab work to kill cancer cells?
HER2 makes the cells grow and divide. Trastuzumab attaches to the HER2 receptor. When this happens it allows the emtansine to go into the cancer cell. Inside the cell emtansine becomes active and kills the cancer cell.
